Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope

J Infect Dis. 1996 Feb;173(2):472-6. doi: 10.1093/infdis/173.2.472.

Abstract

The question of whether persistently seronegative persons at high risk for human immunodeficiency virus type 1 (HIV-1) infection exhibit HIV-1-specific T cell responses and antibodies to HIV-1 envelope epitopes shared with selected HLAs was assessed. These antibodies are not detectable by conventional serologic methods. Envelope-specific helper T (Env-Th) cell responses and antibodies specific for the HIV/HLA epitopes were studied in 21 HIV-1-negative injection drug users (IDUs). HIV/HLA antibodies were detected in 7 (33.3%) of 21 IDUs and 4 (4.3%) of 94 low-risk controls. Env-Th cell responses were detected in 16 (76.2%) of 21 IDUs and in 2 (3.1%) of 65 low-risk controls. All HIV/HLA antibody-positive IDUs also had Env-Th cell responses. These findings confirm the presence of HIV-1-specific immunity in conventionally seronegative individuals. Further characterization of these responses could provide the basis for new preventive strategies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • HIV Antibodies / analysis*
  • HIV Antigens / immunology
  • HIV Infections / immunology*
  • HIV Seronegativity / immunology*
  • HIV-1 / immunology*
  • Histocompatibility Antigens Class I / immunology*
  • Humans
  • Interleukin-2 / biosynthesis
  • Lymphocyte Activation / immunology
  • Risk Factors
  • Substance Abuse, Intravenous / immunology*
  • T-Lymphocytes, Cytotoxic / immunology
  • T-Lymphocytes, Helper-Inducer / immunology*
  • Viral Envelope Proteins / immunology*

Substances

  • HIV Antibodies
  • HIV Antigens
  • Histocompatibility Antigens Class I
  • Interleukin-2
  • Viral Envelope Proteins